Country: Armenia
Language: English
Source: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
hemodialysate from calves blood protein-free
Legacy Pharmaceuticals Switzerland GmbH
առկա չէ (B05ZA)
hemodialysate from calves blood protein-free
42,5mg/ml
solution for i/m and i/v injection
(25/5x5/) ampoules 2ml, blisters
Prescription
Registered
2015-03-25
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT SOLCOSERYL® Injection Solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION COMPOSITION _Active ingredient:_ Protein free haemodialysate of calf blood (_Bos taurus_), chemically and biologically standardized _Excipients:_ Hydrochloric acid 25%, Sodium hydroxide 27%, Water for injections pro 1 ml. 3. GALENIC FORM AND QUANTITY OF ACTIVE SUBSTANCE PER UNIT 1 ml of Solcoseryl Injection Solution (_i.v._) contains 42.5 mg protein free haemodialysate of calf blood (_Bos taurus_), chemically and biologically standardised 1 ampoule of 2 ml contains 85 mg protein free haemodialysate of calf blood, chemically and biologically standardised 1 ampoule of 5 ml contains 212.5 mg protein free haemodialysate of calf blood, chemically and biologically standardised 4. CLINICAL PARTICULARS 4.1 INDICATIONS AND USAGE Peripheral arterial occlusive disease (PAOD) in stages III/IV in patients with contraindications for or intolerance of other vasoactive drugs; Chronic venous insufficiency with therapy resistant leg ulcers 4.2 DOSAGE AND ADMINISTRATION If appropriate to the clinical condition of the patient, it is recommended that Solcoseryl is administered as an intravenous infusion whenever possible and not as an intravenous injection. Solcoseryl Injection Solution must not be administered as a bolus injection. When administered as an infusion or an injection, Solcoseryl Injection Solution should be diluted in a ratio of at least 1:1 with a sodium chloride or glucose solution or with a mixed glucose/sodium chloride solution and administered slowly. Solcoseryl Injection Solution should not be diluted with potassium containing infusion solutions. Infusion: Whenever possible, Solcoseryl should be administered as an intravenous infusion, in particular if the total volume of the diluted solution is more than 40 ml. The speed of the infusion depends on the patient's haemodynamic status. Injection: If administration of Solcoseryl as an injection is unavoidable, the solution sho Read the complete document